Topics

Glioblastoma | Treatment | Clinical trials | Immune Checkpoint Inhibitors

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Immune Checkpoint Inhibitors

Schonfeld E, Choi J, Tran A, Kim LH, Lim M.
The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review.
Neurooncol Adv. 2024 Nov 12;6(1):vdae174. doi: 10.1093/noajnl/vdae174. PMID: 39534539. Review. ˍ

Baskaran AB, Kozel OA, Venkatesh O, Wainwright DA, Sonabend AM, Heimberger AB, Lukas RV.
Immune Checkpoint Inhibitors in Glioblastoma IDHwt Treatment: A Systematic Review.
Cancers (Basel). 2024 Dec 12;16(24):4148. doi: 10.3390/cancers16244148. PMID: 39766048. Review. ˍ

de Melo SM, Elias Nunes da Silva ME, Torloni MR, Riera R, De Cicco K, Latorraca CO, Pinto ACPN.
Anti-PD-1 and anti-PD-L1 antibodies for glioma.
Cochrane Database Syst Rev. 2025 Jan 8;1(1):CD012532. doi: 10.1002/14651858.CD012532.pub2. PMID: 39777725. Meta-analysis˰ ˍ

Gómez EG, Morales MAM, San-Juan D, Romero-Valencia J, Mendez DLR, Hernandez DOL, Pizarro MM, Narvaez ERB, Pelayo-Salazar ME, Jimenez SM.
Efficacy and safety of immune checkpoint inhibitors and mTOR inhibitors as targeted therapy for glioblastoma: A systematic review and meta-analysis of randomized clinical trials.
Neurosurg Rev. 2026 Jan 3;49(1):95. doi: 10.1007/s10143-025-04043-6. PMID: 41484472. Review; Meta-analysis˰ ˍ